A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Li, Yongshu, Li, Fangfei, Jiang, Feng, Lv, Xiaoqing, Zhang, Rongjiang, Lu, Aiping, Zhang, Ge
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4964524/
https://ncbi.nlm.nih.gov/pubmed/27438833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17071151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados